<DOC>
	<DOCNO>NCT01479309</DOCNO>
	<brief_summary>The goal clinical research study expand research follow find high tolerable dose sodium stibogluconate combine interferon alfa-2b treatment patient advance cancer respond standard treatment standard treatment type cancer .</brief_summary>
	<brief_title>Study Evaluate Sodium Stibogluconate With Interferon Alpha-2b</brief_title>
	<detailed_description>Primary objective : To determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) SSG combination IFN alpha2b patient advanced malignancy . Secondary objective : - To correlate AUC SSG clinical toxicity efficacy ; - To quantify effect SSG IFN alpha2b induce gene modulation signal transduction pathway ; - To characterize effect SSG PTPases SHP-1 SHP-2 . To assess safety , efficacy , PK SSG combination IFN alpha2b . Treatment : During Cycle 1 , give sodium stibogluconate day vein Days 1-5 . On Days 8-12 , give sodium stibogluconate day vein , give interferon alfa-2b 3 day injection skin Days 8 , 10 , 12 . For every cycle Cycle 1 , give sodium stibogluconate day vein Days 1-5 8-12 , give interferon alfa-2b 3 day injection skin Days 1 , 3,5 , 8 , 10 , 12 . Treatment cycle last 3 week ( 2 week treatment , follow 1 week treatment ) . After Cycle 1 , schedule return clinic 10 day receive treatment Cycle 2 , follow manner Cycle 1 .</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antimony Sodium Gluconate</mesh_term>
	<criteria>1 . Patients sign write informed consent document able comply study protocol duration study . 2 . Patients histologically cytologically confirm diagnosis malignancy ( patient measurable nonmeasurable disease ) progress follow effective therapy effective therapy exists . 3 . Patients great equal 18 year age . 4 . Patients Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 . 5 . Patients estimated life expectancy 3 month . 6 . Patients normal cardiac ejection fraction , &gt; 50 % estimate 2 D Echocardiogram MUGA . 7 . Patients adequate organ function indicate follow laboratory value obtain within 10 day prior first dose SSG : Granulocytes &gt; /=1,500 microliter , Platelets &gt; /= 100,000 microliter , Hemoglobin &gt; /=9.0 g/dL , Creatinine ( Cr ) &lt; /= 1.5 mg/dL , Bilirubin Normal limit , &lt; 2.0 x ULN liver metastasis , Aspartate aminotransferase ( AST ) &lt; 2.5 * ULN &lt; 5.0 * ULN liver metastasis , Alanine aminotransferase ( ALT ) &lt; 2.5 * ULN &lt; 5.0 * ULN liver metastasis . 1 . Patients concurrent immunotherapy , include IFN therapy ( prior therapy allow &gt; /= 4 month since immunotherapy ) . 2 . Patients receive investigational drug include immunotherapy , gene therapy , hormone therapy , biologic therapy , radiation therapy , chemotherapy , major surgery within 3 week study enrollment 3 . Patients recover acute toxicity previous therapy prior enrollment . 4 . Patients medically uncontrolled cardiovascular illness , unstable angina , congestive heart failure , history myocardial infarction , electrocardiogram ( ECG ) abnormalities suggestive cardiac conduction delay ( QTc &gt; 0.47 second ) , history atrial fibrillation flutter , serious clinically significant cardiac arrhythmia 5 . Patients active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant . 6 . Pregnant lactate woman , fertile woman men unless surgically sterile use effective contraception ; All female patient childbearing potential &lt; 1 year postmenopausal must negative beta human chorionic gonadotropin ( βhCG ) pregnancy test baseline practice medically acceptable method birth control ( oral contraceptive least 3 month , implantation intrauterine device least 2 month , barrier method [ e.g . vaginal diaphragm , vaginal sponge , condom spermicidal jelly ] ) . These must continue 3 month study initiation 7 . Patients use daily glucocorticoid except physiological replacement . 8 . Patients know positive Hepatitis B surface antigen , Hepatitis C human immunodeficiency virus ( HIV ) . 9 . Patients prior history solid organ allograft allogeneic bone marrow transplant . 10 . Patients psychiatric disorder ( ) would interfere consent , study participation , followup . 11 . Patients severe concurrent disease , , judgment investigator , would make patient inappropriate entry study . 12 . Patient symptomatic untreated central nervous system metastasis . 13 . Patients take following medication eligible : Amiodarone ( Cordarone ) ; Disopyramide ( Norpace ) ; Dofetilide ( Tikosyn ) ; Procainamide ( Procanbid , Pronestyl ) ; Quinidine ( Quinaglute ) ; Sotalol ( Betapace ) ; Erythromycin ; Azithromycin ( Zpack ) , cont 'd 14 . Clarithromycin ( Biaxin ) ; Pentamidine ( Pentacarinat ) ; Trimethoprimsulfamethoxazole ( Bactrim ) ; Bepridil ( Vascor ) ; Phenothiazinesprochlorperazine ( Compazine ) , promethazine ( Phenergan ) , chlorpromazine ( Thorazine ) antipsychotic medication ; ButyrophenonesHaloperidol ( Haldol ) , cont 'd 15 . Risperidone ( Risperdal ) ; Tricyclic tetracyclic antidepressants—imipramine ( Tofranil ) , amitriptyline ( Elavil ) , desipramine ( Norpramin ) , nortriptyline ( Pamelor ) ; Monoamine oxidase inhibitor ; High dose methadone ; Arsenic trioxide ; Dolasetron ( Anzemet ) ; Any herbal preparation ; • Chronic need colony stimulate factor ( i.e. , GMCSF ) , erythropoietin use permit . 16 . Patients history hypersensitivity IFN a2b SSG component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Advanced Malignancies</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Phase I Studies</keyword>
	<keyword>Sodium Stibogluconate</keyword>
	<keyword>Interferon Alpha-2b</keyword>
	<keyword>Intron A</keyword>
	<keyword>SSG</keyword>
</DOC>